Global Pharmacovigilance and Risk Management Strategies Conference

North Bethesda, MD
Short Courses: Sunday, January 25
Conference: January 26-28

PROGRAM CHAIR

Mariette Boerstoel-Streefland, MD, MBA, MS
Senior Vice President, Patient Safety Officer
Bristol Myers Squibb

PROGRAM COMMITTEE

Kal Elhoregy, RPh
Senior Director, Global Risk Management & Pharmacovigilance Compliance
Amneal Pharmaceuticals

Michael Forstner, PhD, MPH, MSc
Managing Director, Head of Pharmacoepidemiology Practice
Mesa Laubela-Consulting, Switzerland

Balmeet Gurm, MD
Executive Director, Therapeutic Area Lead Cardiovascular and EBs, Patient Safety
Bristol Myers Squibb

Tarek Hammad, MD, PhD, MS, MSc, FISPE
Vice President, Global Head of Medical Safety, Marketed Products and PDT, PSPV
Takeda Pharmaceuticals

Scott Janiczak, PharmD, MPH
Team Leader, Division of Pharmacovigilance-I, OSE, CDER
FDA

Stephanie Millican, PhD, MSc
Deputy Director Benefit Risk Evaluation, Safety and Surveillance
MHRA, United Kingdom

Mark Perrott, PhD
Managing Partner
Axian Consulting Ltd., United Kingdom

Ranjeeta Sinvhal, MD
Executive Medical Director, Medical Safety
AbbVie

Bethany Van Veen
CEO and Founder
Perspective Pharmacovigilance

Jamie Wilkins, PharmD Head, Risk Management Center of Excellence
Pfizer Inc

PROGRAM ADVISORS

James Buchanan, PharmD
President
Covilance LLC

Barbara Hendrickson, DrMed, MD
Clinical Associate, Pediatric Infectious Diseases
University of Chicago

Overview

Join us for DIA's *Global Pharmacovigilance and Risk Management Strategies Conference*, the leading forum for advancing drug safety and regulatory expertise. Developed with regulators and industry leaders, this event offers insights on global harmonization, AI-driven signal detection, benefit-risk assessment, and real-world evidence for safety monitoring. Learn best practices for optimizing RMPs and REMS, integrating patient perspectives, and managing compliance in resource-constrained settings. Connect with experts, regulators, and patient advocates to explore innovative solutions and stay ahead in pharmacovigilance and risk management.

Event Goals and Offerings

- Provide actionable insights on evolving pharmacovigilance and risk management strategies across global regulatory landscapes
- Highlight real-world applications of advanced technologies such as AI, ML, and real-world data in safety and signal management
- Facilitate regulatory-to-industry dialogue on risk communication, safety assessments, and benefit-risk evaluations
- Equip attendees with the tools to navigate the latest REMS and aRMM guidance and implementation frameworks, including CIOMS XII and the FDA REMS Logic Model

Why You Can't Miss It

- Network with global pharmacovigilance leaders across regulatory agencies, large pharma, small biotech, and public health foundations
- Hear directly from FDA, EMA, MHRA, and other global regulators about the latest policies, guidance, and structural shifts in safety and surveillance
- Engage in case-based discussions around REMS, signal detection, predictive technologies, and the application of real-world evidence in safety monitoring
- Participate in interactive short courses on risk management convergence and benefit-risk planning aligned with CIOMS XII
- Explore global and regional regulatory updates in Asia, Africa, Europe, and the Middle East in a dedicated session

Who Should Attend

Professionals involved in:

- Benefit-risk Assessment and Communication
- Clinical Research
- Data Safety Monitoring and Analysis
- Drug Safety
- Health Outcomes
- Medical Affairs
- Medical Communications
- Medical Information
- Medical Writing
- Medical Product Safety Assessment
- Patient Engagement and Advocacy Groups
- Pharmacoepidemiology
- Pharmacovigilance
- Post-Market Studies
- Quality Assurance
- Quality Control
- Real-World Evidence Generation
- Regulatory Affairs
- Risk Management
- Safety Statistics

Schedule At-A-Glance (All times listed are Eastern Time)

IN-PERSON SHORT COURSE | SUNDAY, JANUARY 25		ROOM
8:30AM-12:00PM	Short Course: Introduction to Benefit–Risk Management: Building Strong Assessments for Smarter Decisions **This Short Course requires an additional registration fee. You do not need to be registered for the conference to attend**	Brookside AB *(Lower Level)*
1:00-4:30PM	Short Course: Translating Global Risk Management Guidance Into Innovation and Patient Safety **This Short Course requires an additional registration fee. You do not need to be registered for the conference to attend**	Brookside AB *(Lower Level)*
DAY ONE | MONDAY, JANUARY 26		**ROOM**
7:30AM-5:00PM	Conference Registration	Grand Ballroom Foyer *(Upper Level)*
7:30-8:30AM	Networking Breakfast	Grand Ballroom A-D
8:30-8:45AM	Welcome and Opening Remarks	Grand Ballroom E-H
8:45-9:30AM	Session 1: Fireside Chat with Dr. Robert Califf: Shaping the Future of Post-Market Safety, Global Harmonization, and More	Grand Ballroom E-H
9:30-10:15AM	Networking Break	Grand Ballroom A-D
9:40-10:10AM	Hosted Session/Non-CE: Case Study Spotlight hosted by	Brookside AB *(Lower Level)*
10:15-11:30AM	Session 2: Navigating FDA & MHRA Regulatory Policy Shifts Updates to Stay Ahead of Compliance	Grand Ballroom E-H
11:30AM-12:30PM	Networking Luncheon	Grand Ballroom A-D
12:30-1:45PM	Session 3: Adapting Risk Minimization Strategies Across the Product Lifecycle	Grand Ballroom E-H
1:45-2:30PM	Networking Break	Grand Ballroom A-D
1:50-2:20PM	Hosted Session/Non-CE: Case Study Spotlight hosted by	Brookside AB *(Lower Level)*
2:30-3:45PM	Session 4: Turning Guidance into Action -- Practical Pathways for Effective Risk Management	Grand Ballroom E-H
3:50-5:05PM	Session 5: Fit-for-Purpose Pharmacovigilance: Real-World Best Practices and Strategic PV Planning for Small and Emerging Companies	Grand Ballroom E-H
5:05-6:05PM	Networking Reception	Grand Ballroom A-D
DAY TWO | TUESDAY, JANUARY 27		**ROOM**
7:45AM-4:15PM	Conference Registration	Grand Ballroom Foyer *(Upper Level)*
7:45-8:30AM	Networking Breakfast	Grand Ballroom A-D
7:55-8:25AM	Hosted Session/Non-CE: Case Study Spotlight hosted by	Brookside AB *(Lower Level)*

8:30-9:45AM	Session 6: Let's Go Global: Regional Regulatory Updates from Africa and the Middle East	Grand Ballroom E-H
9:45-10:30AM	Networking Break	Grand Ballroom A-D
9:50-10:20AM	Hosted Session/Non-CE: Case Study Spotlight hosted by	Brookside AB *(Lower Level)*
10:30-11:45AM	Session 7: Driving Understanding of Human Risk Through Nonclinical Studies in Early Clinical Trials	Grand Ballroom E-H
11:45AM-1:00PM	Networking Luncheon and Roundtable Discussions	Grand Ballroom A-D
1:00-2:15PM	Session 8: What's New in Advancing Signal Detection? Smarter Tools for Safety Evaluation	Grand Ballroom E-H
2:15-3:00PM	Networking Break	Grand Ballroom A-D
2:20-2:50PM	Hosted Session/Non-CE: Case Study Spotlight hosted by	Brookside AB *(Lower Level)*
3:00-4:15PM	Session 9: Harnessing AI and Emerging Tech to Transform Pharmacovigilance	Grand Ballroom E-H
DAY THREE | WEDNESDAY, JANUARY 28		**ROOM**
8:00AM-12:35PM	Conference Registration	Grand Ballroom Foyer *(Upper Level)*
8:00-8:30AM	Networking Breakfast	Grand Ballroom A-D
8:30-9:45AM	Session 10: DIAmond Session: The Safety Pulse: Executive Insights from Global Chief Safety Officers on Maintaining Best-in-Class PV Organizations	Grand Ballroom E-H
9:45-10:20AM	Networking Break	Grand Ballroom A-D
9:50-10:20AM	Hosted Session/Non-CE: Case Study Spotlight hosted by	Brookside AB *(Lower Level)*
10:20-11:20AM	Session 11: Even Big Data Can Feel Small: Addressing Safety Evidence Challenges with Practical RWE Solutions	Grand Ballroom E-H
11:25AM-12:25PM	Session 12: Hot Topics in PV -- Timely Insights Shaping the Future of Safety	Grand Ballroom E-H
12:25-12:35PM	Closing Remarks	Grand Ballroom E-H
12:35PM	Conference Adjourns	

Learning Objectives

- Integrate real-world data and evidence into safety evaluations and regulatory decisions
- Assess the use of AI, ML, and digital tools for signal detection and safety monitoring
- Identify effective methods for communicating safety information and benefit–risk outcomes
- Explain how nonclinical data and NAMs inform early risk assessment
- Discuss strategies for addressing safety challenges in special populations and small organizations
- Summarize key global regulatory and policy updates in pharmacovigilance and risk management
- Apply structured approaches to REMS, aRMMs, and benefit–risk frameworks

Continuing Education Credits

The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This program is designated for up to 21 contact hours or 2.1 continuing education units (CEU's)

ACPE Credit Requests MUST BE SUBMITTED by Friday, March 13, 2026

DIA is required by the Accreditation Council for Pharmacy Education (ACPE) to report pharmacy-requested CEUs through the CPE Monitor system. **All ACPE-certified activity credit requests need to be submitted through DIA's My Transcript within 45-days post activity.** If ACPE credit is not requested by Friday, March 13, 2026, the CEU request will not be transmitted through to the CPE Monitor. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.cpemonitor.net.

ACPE CREDIT REQUESTS MUST BE SUBMITTED BY Friday, March 13, 2026.

Continuing Education Credit Allocation

January 25, 2026 – Short Course: Introduction to Benefit–Risk Management: Building Strong Assessments for Smarter Decisions: ACPE: 3.25 contact hours or .325 CEUs, Type of Activity: Application, 0286-0000-26-003-L04-P
January 25, 2026 – Short Course: Translating Global Risk Management Guidance Into Innovation and Patient Safety: ACPE: 3.25 contact hours or .325 CEUs, Type of Activity: Application, 0286-0000-26-004-L04-P
January 26, 2026 - Global Pharmacovigilance and Risk Management Strategies Conference – Day 1: ACPE: 6 contact hours or .6 CEUs, Type of Activity: Knowledge, 0286-0000-26-005-L04-P
January 27, 2026 - Global Pharmacovigilance and Risk Management Strategies Conference – Day 2: ACPE: 5 contact hours or .5 CEUs, Type of Activity: Knowledge, 0286-0000-26-006-L04-P
January 28, 2026 - Global Pharmacovigilance and Risk Management Strategies Conference – Day 3: ACPE: 3.5 contact hours or .35 CEUs, Type of Activity: Knowledge, 0286-0000-26-007-L04-P

Continuing Legal Education

For attorneys who would like to receive continuing legal education credits for attending the 2026 Global Pharmacovigilance and Risk Management Strategies Conference, please complete your state's application for credit and submit accordingly. If you require additional information, please contact CE@DIAglobal.org.

Statement of Credit

If you would like to receive a statement of credit for the days you attend the conference, you must attend one, two, or all three days of the conference, (in their entirety), sign in at the DIA registration desk each day, upon arrival, and request CE credit online through My Transcript (see instructions below). Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests beginning **Wednesday, February 11.**

If you are claiming CE credit for the conference you must:

1. Attend the short course(s) one, two, or all three days of the conference, (in their entirety)
2. Sign in at the DIA registration desk each day, upon arrival
3. Access your DIA account and select My Transcript to claim your ACPE credit, available on **Wednesday, February 11, 2026**
4. ACPE credit must be submitted by **Friday, March 13, 2026**

DIA Disclosure Policy

It is DIA policy that anyone in a position to control the content of a continuing education activity must disclose to the program audience (1) any relevant financial relationships related to the content of their presentation and/or the educational activity, and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Disclosures will be included in the handout materials. This educational activity may include references to the use of products for indications not approved by the FDA. Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the DIA or any of the manufacturers of products mentioned herein. Faculty for this educational activity was asked to disclose any discussion of unlabeled or unapproved uses of drugs or medical devices. Disclosure statements are included with each speaker's biographical sketch.

DIA staff members have no relevant financial relationships to disclose.

TO ACCESS MY TRANSCRIPT:

- Visit **DIAglobal.org**
- **Sign In** with your DIA User ID and Password
- Select the **Welcome Menu** in the upper right hand corner (where your name appears)
- Select **My Account** from the menu
- Select **My Transcripts** then **Manage My Transcripts**

ACCESS PRESENTATIONS:

- Visit **DIAglobal.org**
- **Sign In** with your DIA User ID and Password
- Select the **Welcome Menu** in the upper right hand corner (where your name appears)
- Select **My Account** from the menu
- Choose **My Presentation**

Please Note: DIA User ID and Password are needed to access presentations. If you have forgotten your DIA User ID and Password, or this is your first time logging into the DIA website, please use our Login Reminder. **Presentations will be available for six months post conference.*

Want to view the detailed agenda? Download DIA's Mobile App!

- Agenda at your fingertips
- Network with Attendees, Speakers, Exhibitors
- Ask questions live during sessions through the session chat function



You will be directed to login to our My DIA Account in order to access the mobile app.

Follow the instructions on screen, or please see the registration desk/contact NAEvents@DIAglobal.org if you need additional assistance.

DIA 2026 is the premier gathering for industry leaders, regulatory authorities, governmental representatives, academia, innovators, and patients. Set against the vibrant backdrop of Philadelphia, PA, DIA 2026 will beckon stakeholders from around the world to converge, collaborate, and catalyze transformative change within the life sciences realm.

At DIA 2026, we will transcend boundaries, inviting diverse voices to the table to address both local and global challenges. From regulatory hurdles to technological innovations, from healthcare disparities to patient-centric solutions, our agenda is comprehensive and forward-thinking.